title: [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
abstract: OBJECTIVE
  To assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms.
  
  
  METHODS
  Fifty BPH patients with OAB symptoms were treated with naftopidil at the dose of 25 mg/d for 6 weeks. A self-controlled clinical trial was conducted. The effectiveness and safety of the drug were observed by comparing the International Prostate Symptom Scores (IPSS), quality of life indexes (QOL), maximum urinary flow rates (Qmax) , average urinary flow rates (Qave), voiding volumes (VV), blood pressures (BP) and heart rates (HR) obtained before and after the treatment.
  
  
  RESULTS
  After 6 weeks' medication, the 46 assessable cases showed an average decrease of 9.75 in IPSS (P < 0.01), 3.97 in voiding symptom score (P < 0.01), 5.78 in urinary storage symptom score (P < 0.01) and 1.95 in QOL (P < 0.01), and a mean increase of 4.29 ml/s in Qmax (P < 0.01), 3.75 ml/s in Qave (P < 0.01) and 55.12 ml/s in VV (P < 0.05). But no significant changes were observed in BP and HR. Only 1 patient (4.35%) experienced the adverse event of dizziness.
  
  
  CONCLUSIONS
  The alphalA/D blocker naftopidil is both effective and safe in the treatment of BPH patients with OAB symptoms.
authors.affiliation: Nanjing MR Center of Urology and Andrology/Department of Urology, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
authors.forename: Jing-ping
authors.initials: JP
authors.lastname: Ge
authors.forename: Jun
authors.initials: J
authors.lastname: Gong
authors.forename: Hong-qing
authors.initials: HQ
authors.lastname: Ma
authors.forename: Wu
authors.initials: W
authors.lastname: Wei
authors.forename: Xue-jun
authors.initials: XJ
authors.lastname: Shang
authors.forename: Zheng-yu
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Song
authors.initials: S
authors.lastname: Xu
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Jian-ping
authors.initials: JP
authors.lastname: Gao
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil